Showing posts with label Hypertension. Show all posts
Showing posts with label Hypertension. Show all posts

Sunday, March 21, 2010

Aggressive measures to treat cholesterol, hypertension in diabetes not beneficial.

Moral of the story: The guidelines are correct.  Meet the recommended levels and you are good to go (if you have diabetes).

Source: AMA Morning Rounds 3/17/2010


Aggressive measures to treat cholesterol, hypertension in diabetes not beneficial.


The Los Angeles Times (3/15, Maugh) reports that for diabetics, "two new reports from a major nationwide trial called ACCORD released Sunday show that lowering either blood pressure or cholesterol levels below current guidelines do not provide additional benefit and, in fact, increase the risk of side effects." And, "a third arm of the study, released two years ago, shows that lowering blood sugar levels excessively actually increases the risk of heart disease." Despite being disappointing, "the findings 'reduce the cost and potential side effects of drug therapy' and mean that patients will not have to work as hard at reducing blood sugars, lipids, and blood pressure, said Dr. Denise Simons-Morton of the National Heart, Lung and Blood Institute, which funded the trial."

Sunday, November 29, 2009

High salt intake directly linked to stroke and cardiovascular disease

Moral of the story: Eat less salt. That's it. Your heart will thank you.

Source: BMJ press releases Monday 23 November to Friday 27 November 2009. Available in full at www.bmj.com

(1) High salt intake directly linked to stroke and cardiovascular disease

(Research: Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies)
http://www.bmj.com/cgi/doi/10.1136/bmj.b4336
(Editorial: The case for population-wide salt reduction gets stronge)
http://www.bmj.com/cgi/doi/10.1136/bmj.b4336

High salt intake is associated with significantly greater risk of both stroke and cardiovascular disease, concludes a study published on bmj.com today.

The link between high salt intake and high blood pressure is well established, and it has been suggested that a population-wide reduction in dietary salt intake has the potential to substantially reduce the levels of cardiovascular disease.

The World Health Organization recommended level of salt consumption is 5 g (about one teaspoon) per day at the population level, yet dietary salt intake in most Western countries is close to 10g per day (and much higher in many Eastern European countries).

Collaborative research conducted by Professor Pasquale Strazzullo at the University of Naples, Italy and Professor Francesco Cappuccio at the University of Warwick, UK analysed the results of 13 published studies involving over 170,000 people that directly assessed the relationship between levels of habitual salt intake and rates of stroke and cardiovascular disease.

Differences in study design and quality were taken into account to minimise bias.

Their analysis shows unequivocally that a difference of 5 g a day in habitual salt intake is associated with a 23% difference in the rate of stroke and a 17% difference in the rate of total cardiovascular disease.

Based on these results, the authors estimate that reducing daily salt intake by 5 g at the population level could avert one and a quarter million deaths from stroke and almost three million deaths from cardiovascular disease each year. Furthermore, because of imprecision in measurement of salt intake, these effect sizes are likely to be underestimated, say the authors.

These results support the role of a substantial population reduction in salt intake for the prevention of cardiovascular disease, they conclude.

This study is a useful and welcome addition to the medical literature, and strengthens the case for population-wide salt reduction, says Professor Lawrence Appel from Johns Hopkins University, in an accompanying editorial.

Contacts:
Research: Pasquale Strazzullo, Professor of Medicine, Department of Clinical and Experimental Medicine, "Federico II" ESH Excellence Centre of Hypertension, University of Naples Medical School, Naples, Italy
Email: strazzul@unina.it

Editorial: Lawrence Appel, Professor of Medicine (via Stephanie Desmon, Senior Media Relations Representative), Johns Hopkins University, Baltimore, MD, USA
Email: sdesmon1@jhmi.edu

Monday, March 23, 2009

Very low LDL and normal BP result in slowest progression of atherosclerosis

Moral of the story: 2 thing - Blood Pressure, LDL. Worry about those two things. Get them back to normal and you will go a long way towards preventing heart disease.

Heartwire - Clinical cardiology
Very low LDL and normal BP result in slowest progression of atherosclerosis
March 23, 2009 | Michael O'Riordan

Cleveland, OH - Patients with coronary artery disease (CAD) who reduce LDL cholesterol to very low levels and achieve a normal systolic blood pressure have the slowest progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS), a new study has shown [1]. The findings, according to investigators, support the need for intensive management of global risk in patients with CAD.

"What's happened in recent years with the advent of more potent statins and all the education done around that is that getting people to LDL goal is achieved fairly well," senior investigator Dr Steven Nissen (Cleveland Clinic, OH) told heartwire. "But getting people to dual goals is not done well around the country. We wanted to tell people that there really is some pretty good evidence here that if you get your blood pressure down to normal and your LDL down below 70, this is a disease that can not only be halted, but potentially can even regress."

The results of the study are published in the March 24, 2009 issue of the Journal of the American College of Cardiology.


Seven studies rolled into one

To clarify the relationship between LDL cholesterol and systolic blood pressure and their effects on coronary plaque progression, the researchers, led by Dr Adnan Chhatriwalla (Cleveland Clinic) studied 3437 patients with established CAD enrolled in seven clinical trials. The studies included REVERSAL, CAMELOT, ACTIVATE, ASTEROID, ILLUSTRATE, PERISCOPE, and STRADIVARIUS, a group of trials that investigated statins, acyl coenzyme A:cholesterol acyltransferase (ACAT) and cholesteryl ester transfer protein (CETP) inhibitors, rimonabant, ACE inhibitors, and calcium-channel blockers, among others.

Patients were stratified into four groups based on their average on-treatment LDL-cholesterol levels and systolic blood pressure:

  • LDL cholesterol <70 mg/dL and systolic blood pressure <120 mm Hg.
  • LDL cholesterol <70 mg/dL and systolic blood pressure >120 mm Hg.
  • LDL cholesterol >70 mg/dL and systolic blood pressure <120 mm Hg.
  • LDL cholesterol >70 mg/dL and systolic blood pressure >120 mmHg.

Changes in atheroma burden were monitored by IVUS, which was measured at baseline and at 18 to 24 months.

Patients with very low LDL-cholesterol levels and normal systolic blood pressure, group 1, had the least progression in percent atheroma volume (PAV) and total atheroma volume (TAV). In addition, these patients also had less frequent atheroma progression and more frequent regression. In patients with systolic blood pressure >120 mm Hg who still had very low LDL cholesterol levels, group 2, less progression of PAV and TAV was also observed.

"It really makes a big difference if you can get both down," said Nissen. "It's a big payoff for patients if physicians are diligent about getting LDL and blood pressure under control."

Among patients with LDL-cholesterol levels >70 mg/dL, normal systolic blood pressure was associated with no greater reduction in PAV or TAV, suggesting that lipid lowering has a larger impact than blood-pressure control on plaque progression, findings supported by recent clinical trials.

The findings challenge current treatment recommendations for hypertension, noted Nissen, and he recommends treating prehypertensive patients with coronary disease, those with pressures of 120 to 139 mm Hg systolic or 80 to 89 mm Hg diastolic. In the CAMELOT study, he points out, the calcium-channel blocker amlodipine decreased the risk of cardiovascular events in patients with CAD and normal blood pressure, as did the ACE inhibitor enalapril, but to a lesser extent.

"Remember that these are all people who have coronary artery disease," said Nissen. "These are not your typical primary-prevention patients with hypertension. They already have atherosclerotic disease in their coronaries. We think the evidence is pretty strong that if you already have plaques in your coronaries, you really to have a lower blood-pressure target. . . . Our IVUS data suggest that there is opportunity here to help patients."

Nissen admitted that the issue needs to be studied further and that the ongoing AQUARIUS study will assess changes in atherosclerotic disease progression with aliskiren (Tekturna, Novartis) when given in addition to standard therapy in CAD patients with prehypertension.


More data still needed

In an editorial accompanying the published study, Drs Jonathan Tobis and Alice Perlowski (University of California, Los Angeles) write that human and animal data make clear that a combination of aggressive lipid and blood-pressure control are necessary for a maximum attenuation of plaque progression, improved endothelial function, and reduced inflammation caused by oxidative stress [2].

Regarding the treatment of prehypertensive patients, Tobis and Perlowski write that a lack of data has contributed to a delayed acceptance of the need for drug therapy. In addition to AQUARIUS, the ongoing SPRINT, which is comparing intensive blood-pressure control (<120>130 mm Hg who have one additional risk factor, will help answer those questions.

The editorialists note that plaque progression/regression on IVUS is helpful in determining whether or not clinicians are helping their patients, but hard clinical end points are still needed, especially as they are shown to correspond with predictions based on the IVUS surrogates. Until then, "conclusions derived from these trials should be considered inferential, to be used as guides for future trials focused on clinical-outcomes measures," they write.

Asked about the polypill, Nissen told heartwire that he was not an initial fan, but with these and other data, he is starting to warm up to it. "The idea of having something that you go and get for $10 for three months that would control your blood pressure and your lipids, this study makes the case that it might make some sense."

New results about a polypill approach for primary prevention, combining a BP-lowering drug, a statin, and aspirin in a single pill, will be presented at the American College of Cardiology 2009 meeting next week.

Nissen reports receiving research support from AstraZeneca, Eli Lilly, Pfizer, Takeda, Sankyo, and Sanofi-Aventis and that he donates honoraria, consulting fees, and other payments directly to charity. Chhattriwalla reports no conflicts.
Sources
  1. Chhatriwalla AK, Nicholls SJ, Wang TH, et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol 2009; 53: 1110-1115.
  2. Tobis JM, Perlowski A. Atheroma volume by intravascular ultrasound as a surrogate for clinical endpoints. J Am Coll Cardiol 2009; 53: 1116-1118.

Wednesday, March 18, 2009

Metabolic disorders linked to cognitive decline

Moral of the story: Manage your chronic diseases! Stay on top of treatment, exercise and see your doctor. The last thing you want on top of diabetes is Alzheimer's disease.

Metabolic disorders linked to cognitive decline
March 17, 2009 Allison Gandey
Edited from Medscape Medical News—a professional news service of WebMD

New York, NY and Seattle, WA - Evidence is mounting that metabolic and neurological diseases share common risk factors, according to two studies in the March 2009 issue of the Archives of Neurology.
"Preventing heart disease, stroke, and diabetes—or making sure these conditions are well managed in patients diagnosed with them—can potentially slow the disease progression of Alzheimer's," senior author on one of the studies, Dr Yaakov Stern (Columbia University, New York), said in a news release. Stern et al, led by Dr Elizabeth Helzner (Columbia University) hypothesized that vascular factors such as heart disease, stroke, diabetes, hypertension, smoking, and blood lipid levels may predict the progression of Alzheimer's disease [1]. The group studied 156 patients followed for a mean of 3.5 years. Participants were from the Washington Heights and Inwood Columbia Aging Project, a multiethnic, community-based, prospective study of aging in northern Manhattan.
Researchers found that patients with a history of diabetes and elevated levels of cholesterol, especially LDL cholesterol, had faster cognitive decline. In fact, each 10-U increase in cholesterol and LDL cholesterol was associated with a 0.10-standard-deviation decrease in cognitive score per year of follow-up (p<0.001 for total cholesterol; p=0.001 for LDL cholesterol).
Investigators found that a history of heart disease and stroke were associated with cognitive decline only in carriers of the APOE e4 allele.
"These findings indicate that controlling vascular conditions may be one way to delay the course of Alzheimer's, which would be a major development in the treatment of this devastating disease," Stern said.Fluctuations in weight may boost dementia risk
In the second study published in the same issue of the Archives of Neurology, investigators show that obese middle-aged adults and underweight elderly people have an increased dementia risk [2].
Using data from the Cardiovascular Health Study, researchers studied the body-mass index (BMI) of participants at mid- and late life. Patients were from a community-dwelling sample at four US sites.
Investigators included 2798 people. Of these, 480 had incident dementia, 245 had Alzheimer's disease, and 213 had vascular dementia.
They found that middle-aged patients who were obese had an increased risk for dementia (BMI >30 vs normal-weight BMI 20 to 25), adjusted for demographics (hazard ratio 1.39; 95% CI 1.03-1.87), although this observation was weakened after adjustment for cardiovascular risk factors (hazard ratio 1.36; 95% CI 0.94-1.95).
These results help explain the 'obesity paradox.'
But the risk estimates were reversed in assessments of late-life BMI. Underweight people, those with a BMI of less than 20, had an increased risk for dementia (hazard ratio 1.62; 95% CI 1.02-2.64). Surprisingly, being overweight later in life was not associated with an increased risk (hazard ratio 0.92; 95% CI 0.72-1.18), and being obese reduced the risk for dementia (hazard ratio 0.63; 95% CI 0.44-0.91).
"These results help explain the 'obesity paradox,' " the researchers, led by Dr Annette Fitzpatrick (University of Washington, Seattle), write. "Differences in dementia risk across time are consistent with physical changes in the trajectory toward disability."
These findings suggest that the predictive ability of BMI changes across time, they note
"Weight loss occurs with comorbidities at older ages and is often reflective of poor health," write Fitzpatrick and her team. "Weight loss, along with psychological, behavioral, and mobility problems, is one of the principal manifestations of Alzheimer's disease. Weight loss may predate dementia onset by as much as 10 years."
The researchers conclude: "These results reinforce the necessity of monitoring weight loss closely in older adults."
The complete contents of Medscape Medical News, a professional news service of WebMD, can be found at www.medscape.com, a website for medical professionals.
Sources
Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66:343-348.
Fitzpatrick AL, Kuller LH, Lopez OL, Midlife and late-life obesity and the risk of dementia: cardiovascular health study. Arch Neurol 2009; 66:336-342.
Related links
Adherence to Mediterranean diet reduces risk of major chronic diseases [Prevention > Prevention; Sep 12, 2008]
Heart disease linked to poor cognitive function in middle age [Brain/Kidney/Peripheral > Brain/Kidney/Peripheral; Jul 23, 2008]
Low HDL-C associated with poor memory [HeartWire > Brain/Kidney/Peripheral; Jun 30, 2008]
High cholesterol linked to increased AD risk [HeartWire > Medscape Medical News; Nov 06, 2006]
Low cholesterol linked to reduced cognitive function [HeartWire > News; Mar 23, 2005]
Lipid metabolism abnormalities observed in brain aging and Alzheimer's disease [HeartWire > News; Feb 15, 2004]

Tuesday, December 30, 2008

Does It Matter How Hypertension Is Controlled?

Moral of the story: The ACCOMPLISH trial showed new outcomes data that is not consistent with previous data, where there were no differences in benefit received as long as the drop in blood pressure was equivalent. It can't hurt to follow the results of the new data, so I would go with that.

Does It Matter How Hypertension Is Controlled?
Aram V. Chobanian, M.D.

Hypertension is one of the most important risk factors for cardiovascular and renal diseases. Currently, approximately 73 million adults in the United States and approximately 1 billion adults worldwide have hypertension, and the prevalence is increasing.1 Many clinical trials have examined the effects of antihypertensive drugs. Studies comparing the effects of antihypertensive medications with those of placebo have shown consistently that lowering blood pressure is associated with major reductions in the incidence of coronary events, strokes, and congestive heart failure.2 These benefits have been observed irrespective of age, sex, severity of the hypertension, presence or absence of associated risk factors or concomitant diseases, or class of antihypertensive drug used. However, the results of trials comparing the effects of different antihypertensive drugs or drug regimens have not been as consistent.

The initial findings from a new drug comparison study, the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial (ClinicalTrials.gov number, NCT00170950 [ClinicalTrials.gov] ), are reported in this issue of the Journal.3 The ACCOMPLISH trial was a randomized, double-blind, industry-sponsored study involving subjects with hypertension that examined the effects on cardiovascular outcomes of treatment with the angiotensin-converting–enzyme (ACE) inhibitor benazepril combined with either the calcium-channel blocker amlodipine or the diuretic hydrochlorothiazide. Somewhat surprisingly, as compared with the benazepril–hydrochlorothiazide group, the group that was treated with benazepril and amlodipine had a relative risk reduction of approximately 20%, and an absolute risk reduction of 2.2%, in the primary end point, a composite of illness and death from cardiovascular causes. The secondary end point of death from cardiovascular causes and nonfatal myocardial infarction and stroke showed a similar benefit.

The ACCOMPLISH study population was at high risk for cardiovascular diseases. The average age at entry was 68 years, and participants with a history of ischemic heart disease, peripheral vascular disease, stroke, left ventricular hypertrophy, or diabetes (which was present in 60% of the subjects) were included. Because the study design did not include a drug washout period, data on pretreatment blood-pressure levels were unavailable. However, most subjects probably had relatively severe hypertension; at study entry, 38% were receiving three or more antihypertensive drugs, yet only 37% had blood-pressure levels less than 140/90 mm Hg.

Most previous comparison trials have failed to show significant differences in the primary outcomes as long as equivalent decreases in blood pressure were achieved with the different drug regimens. Selected examples include the Swedish Trial in Old Patients with Hypertension-2 (STOP-2) trial, a study that examined treatment with diuretics and beta-blockers as compared with treatment with ACE inhibitors and calcium-channel blockers in elderly subjects with hypertension4; the International Verapamil-Trandolapril Study (INVEST) (NCT00133692 [ClinicalTrials.gov] ), a trial in which a regimen of verapamil with or without trandolapril was compared with a regimen of atenolol with or without hydrochlorothiazide among patients with hypertension and coronary heart disease5; and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) (NCT00000542 [ClinicalTrials.gov] ), which compared chlorthalidone, lisinopril, and amlodipine therapies.6 In none of these trials did the primary outcomes differ between regimens. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), which compared treatment with the combination of amlodipine and perindopril with treatment with the combination of atenolol and bendroflumethiazide, the primary outcome of fatal coronary heart disease and nonfatal myocardial infarction also did not differ significantly between the two treatment groups; the composite secondary outcomes, which included stroke, were less favorable in the atenolol–bendroflumethiazide group, which also had average blood-pressure levels that were approximately 3 mm Hg systolic and 2 mm Hg diastolic higher than those of subjects in the amlodipine–perindopril group.7 In contrast, in the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study (NCT00338260 [ClinicalTrials.gov] ), the primary cardiovascular outcomes (particularly stroke) with treatment with the angiotensin-receptor blocker losartan were better than those with atenolol therapy, even though there were similar reductions in blood pressure in the two groups.8 In the Second Australian National Blood Pressure Study, ACE-inhibitor therapy was associated with a somewhat lower incidence of cardiovascular events than thiazide-based treatment, although the benefit was observed only in men.9

No previous outcome trial has compared treatment with a combination of an ACE inhibitor and a calcium-channel blocker with treatment with the combination of an ACE inhibitor and a thiazide-type diuretic. ALLHAT compared chlorthalidone therapy with amlodipine therapy, though not in combination with an ACE inhibitor. The chlorthalidone dose used in ALLHAT and the hydrochlorothiazide dose used in the ACCOMPLISH trial were both in a range of 12.5 to 25.0 mg per day. Chlorthalidone is estimated to have double the potency of hydrochlorothiazide and a much longer duration of effect in this dose range. A recent study used 24-hour ambulatory blood-pressure measurements to study the effects of chlorthalidone (25 mg per day) as compared with hydrochlorothiazide (50 mg per day).10 Although blood-pressure levels measured during the daytime in the clinician's office were similar, blood-pressure levels measured during the nighttime, and 24-hour average blood pressures, were considerably lower with chlorthalidone than with hydrochlorothiazide. The reported blood-pressure levels measured in the clinician's office in the ACCOMPLISH trial were also relatively similar in the two treatment groups, but the possibility exists that the relatively low dose of hydrochlorothiazide used (averaging 19 mg per day) did not provide 24-hour blood-pressure control that was as effective as that provided by the benazepril–amlodipine regimen. Ambulatory blood-pressure measurements were apparently included in the design of the ACCOMPLISH trial,11 and the data, if available, could address this issue in the future.

Experimental evidence has suggested that ACE inhibitors and calcium-channel blockers can have vasoprotective effects. These agents have been shown to inhibit atherosclerosis in various animal models with hypercholesterolemia and to improve endothelium-dependent vasodilatation in isolated arteries and in patients with vascular disease.12,13 Diuretics do not share these properties. However, the clinical relevance of these findings is uncertain.

Are the results from the ACCOMPLISH trial applicable to the general population with hypertension? As noted above, the study participants were older and had relatively severe hypertension and a high prevalence of cardiovascular disease and diabetes. Although this group of subjects clearly does not mirror the broader population with hypertension, the same criticism can be applied to the other trials as well. Treatment recommendations should be based on the total available evidence rather than on the results of any single trial.

The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, published in 2003, included a strong preference for thiazide-type diuretics as the initial therapy for most patients with hypertension in the absence of compelling indications for specific drugs.14 However, it is time to reexamine these recommendations. The results from the many recent studies, including the ACCOMPLISH trial, when considered together, suggest that greater flexibility is now indicated in the choice of the initial drug. In my opinion, each of the major classes (diuretics, ACE inhibitors, calcium-channel blockers, angiotensin-receptor blockers, and, to a lesser extent, beta-blockers) appears reasonable as first-line therapy. The choice of a drug should depend on criteria such as compelling indications or contraindications, coexisting conditions, adverse effects, race, and the clinician's experience. Nevertheless, increased flexibility in choice should not negate the importance of diuretics, which have been a cornerstone of antihypertensive therapy for the past 50 years. The data from the ACCOMPLISH trial also should not diminish the value of treatment with the combination of an ACE inhibitor and a diuretic, a combination that effectively lowers blood pressure and that was recently shown to produce major reductions in mortality and morbidity in the very old.15

Many excellent medications are available to control hypertension. These drugs have acceptable side-effect and adverse-event profiles, and many are now available in generic versions, making cost less of an issue in the selection of a drug. Most patients with hypertension will require two or more drugs to control their hypertension, and combination drug formulations may also be useful. Although specific benefits may be provided by a given drug or drug combination, the evidence is overwhelming that the most important aspect of treatment is to reduce blood pressure to goal levels. How this is achieved is less important. Unfortunately, despite the remarkable progress in therapy, blood pressure remains inadequately controlled in almost two thirds of patients with hypertension in the United States. We must do better.

Dr. Chobanian reports serving as chair for the seventh report of the Joint National Committee, which developed guidelines for the management of hypertension, and receiving a lecture fee from Bristol-Myers Squibb of Mexico. No other potential conflict of interest relevant to this article was reported.


Source Information

From the Department of Medicine, Boston University School of Medicine, and the Boston University Medical Center, Boston.

References

  1. Heart disease and stroke statistics: 2008 update at-a-glance. Dallas: American Heart Association, 2008. (Accessed November 13, 2008, at http://www.americanheart.org/downloadable/heart/1200082005246HS_Stats%202008.final.pdf.)
  2. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005;165:1410-1419. [Free Full Text]
  3. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008;359:2417-2428. [Free Full Text]
  4. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-1756. [CrossRef][ISI][Medline]
  5. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003;290:2805-2816. [Free Full Text]
  6. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997. [Erratum, JAMA 2003;289:178, 2004;291:2196.] [Free Full Text]
  7. Dahlöf B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906. [CrossRef][ISI][Medline]
  8. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003. [CrossRef][ISI][Medline]
  9. Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-592. [Free Full Text]
  10. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006;47:352-358. [Free Full Text]
  11. Jamerson KA, Bakris GL, Wun CC, et al. Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension. Am J Hypertens 2004;17:793-801. [ISI][Medline]
  12. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990;15:327-331. [Free Full Text]
  13. Lüscher TF, Wenzel RR, Moreau P, Takase H. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardiovasc Drugs Ther 1995;3:509-523.
  14. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572. [Erratum, JAMA 2003;290:197.] [Free Full Text]
  15. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-1898. [Free Full Text]

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

Moral of the story: it matters what medications you are taking for high blood pressure. Talk to your physician about whether your regimen adheres to the recommendations of the ACCOMPLISH trial.

NEJM -- Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients

Kenneth Jamerson, M.D., Michael A. Weber, M.D., George L. Bakris, M.D., Björn Dahlöf, M.D., Bertram Pitt, M.D., Victor Shi, M.D., Allen Hester, Ph.D., Jitendra Gupte, M.S., Marjorie Gatlin, M.D., Eric J. Velazquez, M.D., for the ACCOMPLISH Trial Investigators

ABSTRACT

Background The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting–enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus a thiazide diuretic.

Methods In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.

Results The baseline characteristics of the two groups were similar. The trial was terminated early after a mean follow-up of 36 months, when the boundary of the prespecified stopping rule was exceeded. Mean blood pressures after dose adjustment were 131.6/73.3 mm Hg in the benazepril–amlodipine group and 132.5/74.4 mm Hg in the benazepril–hydrochlorothiazide group. There were 552 primary-outcome events in the benazepril–amlodipine group (9.6%) and 679 in the benazepril–hydrochlorothiazide group (11.8%), representing an absolute risk reduction with benazepril–amlodipine therapy of 2.2% and a relative risk reduction of 19.6% (hazard ratio, 0.80, 95% confidence interval [CI], 0.72 to 0.90; P<0.001).> of death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke, the hazard ratio was 0.79 (95% CI, 0.67 to 0.92; P=0.002). Rates of adverse events were consistent with those observed from clinical experience with the study drugs.

Conclusions The benazepril–amlodipine combination was superior to the benazepril–hydrochlorothiazide combination in reducing cardiovascular events in patients with hypertension who were at high risk for such events. (ClinicalTrials.gov number, NCT00170950 [ClinicalTrials.gov] .)